Lista de obras - Olivier Kosmider - Dominio Público Uruguay

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

artículo científico publicado en 2013

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

artículo científico publicado en 2014

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

scientific article published on 01 July 2019

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis

artículo científico publicado en 2016

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

artículo científico publicado en 2014

Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia.

artículo científico publicado en 2009

An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

artículo científico publicado en 2016

Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias

scientific article published on 27 August 2009

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

artículo científico publicado en 2016

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

artículo científico publicado en 2016

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

artículo científico publicado en 2018

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

artículo científico publicado en 2013

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

scientific article published on 20 March 2019

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

artículo científico publicado en 2015

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

artículo científico publicado en 2015

Clonal architecture of chronic myelomonocytic leukemias

artículo científico publicado en 2013

Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.

artículo científico publicado en 2011

Dyserythropoiesis of myelodysplastic syndromes

artículo científico publicado en 2017

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

artículo científico publicado en 2015

Efficacy of 5-Azacytidine in aTET2mutated angioimmunoblastic T cell lymphoma

artículo científico publicado en 2014

Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase

artículo científico publicado en 2009

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

artículo científico publicado en 2013

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.

artículo científico publicado en 2013

From mice to human: the "two-hit model" of leukemogenesis

artículo científico publicado en 2006

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

artículo científico publicado en 2010

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

artículo científico publicado en 2011

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

artículo científico publicado en 2020

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

artículo científico publicado en 2010

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

artículo científico publicado en 2013

Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.

artículo científico publicado en 2005

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

artículo científico publicado en 2015

Leukemic phase of follicular lymphomas: an atypical presentation.

artículo científico publicado en 2011

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

artículo científico publicado en 2012

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

artículo científico publicado en 2014

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

artículo científico publicado en 2012

Mutations des gènes impliqués dans l’épissage dans les hémopathies malignes humaines

article

Mutations of ETNK1 in aCML and CMML.

artículo científico publicado en 2015

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients

artículo científico publicado en 2022

Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

artículo científico publicado en 2006

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

artículo científico publicado en 2015

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

artículo científico publicado en 2018

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

artículo científico publicado en 2013

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

artículo científico publicado en 2017

Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.

artículo científico publicado en 2016

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

artículo científico publicado en 2013

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

artículo científico publicado en 2011

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate

artículo científico publicado en 2006

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

artículo científico publicado en 2013

Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation

artículo científico publicado en 2007

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

artículo científico publicado en 2012

Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.

artículo científico publicado en 2013

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

scientific article published on October 2009

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

artículo científico publicado en 2009

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

scientific article published on 11 January 2019

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket

artículo científico publicado en 2013

Lista de obras de Olivier Kosmider

A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).

A common alternative splicing signature is associated with SF3B1 mutations in malignancies from different cell lineages.

A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome

APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis

ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients.

Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia.

An miRNA-DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

Analyses of TET2 mutations in post-myeloproliferative neoplasm acute myeloid leukemias

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?

Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.

Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Clonal architecture of chronic myelomonocytic leukemias

Defective nuclear localization of Hsp70 is associated with dyserythropoiesis and GATA-1 cleavage in myelodysplastic syndromes.

Dyserythropoiesis of myelodysplastic syndromes

Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion

Efficacy of 5-Azacytidine in aTET2mutated angioimmunoblastic T cell lymphoma

Erythropoietin down-regulates stem cell factor receptor (Kit) expression in the leukemic proerythroblast: role of Lyn kinase

Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes.

From mice to human: the "two-hit model" of leukemogenesis

Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.

Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.

Leukemic phase of follicular lymphomas: an atypical presentation.

Localization of the NRAS:BCL-2 complex determines anti-apoptotic features associated with progressive disease in myelodysplastic syndromes

Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study.

Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia.

Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Mutations des gènes impliqués dans l’épissage dans les hémopathies malignes humaines

Mutations of ETNK1 in aCML and CMML.

Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients

Phosphatidylinositol 4-phosphatase type II is an erythropoietin-responsive gene.

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia

Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.

Prognostic score including gene mutations in chronic myelomonocytic leukemia.

RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Response to 5-azacytidine in a patient with TET2-mutated angioimmunoblastic T-cell lymphoma and chronic myelomonocytic leukaemia preceded by an EBV-positive large B-cell lymphoma.

SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias.

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications

Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate

Somatic mutations and epigenetic abnormalities in myelodysplastic syndromes.

Spi-1/PU.1 participates in erythroleukemogenesis by inhibiting apoptosis in cooperation with Epo signaling and by blocking erythroid differentiation

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia.

Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

Tyrosine kinase inhibitors induce down-regulation of c-Kit by targeting the ATP pocket